Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (age)-injected rats

S. Yamagishi, M. Takeuchi, Hiroyoshi Inoue

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Diabetic nephropathy is a leading cause of end-stage renal disease in industrialized countries. Although the molecular mechanisms for the development and progression of diabetic nephropathy are not fully understood, the formation and accumulation of advanced glycation end products (AGEs) have been considered to play a major role in the pathogenesis of diabetic nephropathy. Hypertension is also an independent risk factor for the progression of diabetic nephropathy. However, functional cross-talk between AGEs and blood pressure and their involvement in diabetic nephropathy remain to be elucidated. In this study, we examined the effects of oral administration of azelnidipine, a commercially available dihydropyridine-based calcium antagonist, on renal injury in AGE-treated rats. Administration of azelnidipine inhibited the increase of systolic and diastolic blood pressure levels and urinary N-acetly-β-D-glucosaminidase activity in exogenously AGE-injected rats. Furthermore, azelnidipine treatment also prevented glomerulosclerosis in AGE-treated rats. These results indicate that renal damage in AGE-injected rats could be mediated, at least in part, by the elevation of blood pressure. Our present study suggests that azelnidipine would represent a valuable drug for the treatment of diabetic nephropathy by blocking the deleterious effects of AGEs.

Original languageEnglish
Pages (from-to)137-143
Number of pages7
JournalInternational Journal of Tissue Reactions
Volume27
Issue number3
Publication statusPublished - 2005
Externally publishedYes

Fingerprint

Advanced Glycosylation End Products
Diabetic Nephropathies
Calcium
Blood Pressure
Kidney
Hexosaminidases
Developed Countries
Chronic Kidney Failure
Oral Administration
1,4-dihydropyridine
azelnidipine
Hypertension
Wounds and Injuries
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Physiology
  • Cell Biology
  • Immunology
  • Immunology and Allergy

Cite this

@article{945de812150d477591329337fe04b783,
title = "Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (age)-injected rats",
abstract = "Diabetic nephropathy is a leading cause of end-stage renal disease in industrialized countries. Although the molecular mechanisms for the development and progression of diabetic nephropathy are not fully understood, the formation and accumulation of advanced glycation end products (AGEs) have been considered to play a major role in the pathogenesis of diabetic nephropathy. Hypertension is also an independent risk factor for the progression of diabetic nephropathy. However, functional cross-talk between AGEs and blood pressure and their involvement in diabetic nephropathy remain to be elucidated. In this study, we examined the effects of oral administration of azelnidipine, a commercially available dihydropyridine-based calcium antagonist, on renal injury in AGE-treated rats. Administration of azelnidipine inhibited the increase of systolic and diastolic blood pressure levels and urinary N-acetly-β-D-glucosaminidase activity in exogenously AGE-injected rats. Furthermore, azelnidipine treatment also prevented glomerulosclerosis in AGE-treated rats. These results indicate that renal damage in AGE-injected rats could be mediated, at least in part, by the elevation of blood pressure. Our present study suggests that azelnidipine would represent a valuable drug for the treatment of diabetic nephropathy by blocking the deleterious effects of AGEs.",
author = "S. Yamagishi and M. Takeuchi and Hiroyoshi Inoue",
year = "2005",
language = "English",
volume = "27",
pages = "137--143",
journal = "International Journal of Tissue Reactions",
issn = "0250-0868",
publisher = "Bioscience Ediprint Inc.",
number = "3",

}

TY - JOUR

T1 - Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (age)-injected rats

AU - Yamagishi, S.

AU - Takeuchi, M.

AU - Inoue, Hiroyoshi

PY - 2005

Y1 - 2005

N2 - Diabetic nephropathy is a leading cause of end-stage renal disease in industrialized countries. Although the molecular mechanisms for the development and progression of diabetic nephropathy are not fully understood, the formation and accumulation of advanced glycation end products (AGEs) have been considered to play a major role in the pathogenesis of diabetic nephropathy. Hypertension is also an independent risk factor for the progression of diabetic nephropathy. However, functional cross-talk between AGEs and blood pressure and their involvement in diabetic nephropathy remain to be elucidated. In this study, we examined the effects of oral administration of azelnidipine, a commercially available dihydropyridine-based calcium antagonist, on renal injury in AGE-treated rats. Administration of azelnidipine inhibited the increase of systolic and diastolic blood pressure levels and urinary N-acetly-β-D-glucosaminidase activity in exogenously AGE-injected rats. Furthermore, azelnidipine treatment also prevented glomerulosclerosis in AGE-treated rats. These results indicate that renal damage in AGE-injected rats could be mediated, at least in part, by the elevation of blood pressure. Our present study suggests that azelnidipine would represent a valuable drug for the treatment of diabetic nephropathy by blocking the deleterious effects of AGEs.

AB - Diabetic nephropathy is a leading cause of end-stage renal disease in industrialized countries. Although the molecular mechanisms for the development and progression of diabetic nephropathy are not fully understood, the formation and accumulation of advanced glycation end products (AGEs) have been considered to play a major role in the pathogenesis of diabetic nephropathy. Hypertension is also an independent risk factor for the progression of diabetic nephropathy. However, functional cross-talk between AGEs and blood pressure and their involvement in diabetic nephropathy remain to be elucidated. In this study, we examined the effects of oral administration of azelnidipine, a commercially available dihydropyridine-based calcium antagonist, on renal injury in AGE-treated rats. Administration of azelnidipine inhibited the increase of systolic and diastolic blood pressure levels and urinary N-acetly-β-D-glucosaminidase activity in exogenously AGE-injected rats. Furthermore, azelnidipine treatment also prevented glomerulosclerosis in AGE-treated rats. These results indicate that renal damage in AGE-injected rats could be mediated, at least in part, by the elevation of blood pressure. Our present study suggests that azelnidipine would represent a valuable drug for the treatment of diabetic nephropathy by blocking the deleterious effects of AGEs.

UR - http://www.scopus.com/inward/record.url?scp=28444481059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444481059&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 137

EP - 143

JO - International Journal of Tissue Reactions

JF - International Journal of Tissue Reactions

SN - 0250-0868

IS - 3

ER -